162 related articles for article (PubMed ID: 26266885)
1. Concurrent use of strontium-89 with external beam radiotherapy for multiple bone metastases: early experience.
Heianna J; Toita T; Endo W; Kasuya G; Ariga T; Hashimoto S; Maemoto H; Terui K; Miura N; Togashi A; Miyauchi T; Murayama S
Ann Nucl Med; 2015 Dec; 29(10):848-53. PubMed ID: 26266885
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of strontium-89 palliative therapy in patients with painful bone metastases.
Zorga P; Birkenfeld B; Listewnik MH; Piwowarska-Bilska H
Ann Acad Med Stetin; 2011; 57(1):49-53; discussion 53. PubMed ID: 22593991
[TBL] [Abstract][Full Text] [Related]
3. Palliation of bone pain in patients with metastatic cancer using strontium-89 (Metastron).
Kan MK
Cancer Nurs; 1995 Aug; 18(4):286-91. PubMed ID: 7545083
[TBL] [Abstract][Full Text] [Related]
4. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
Brundage MD; Crook JM; Lukka H
Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
[TBL] [Abstract][Full Text] [Related]
5. The treatment of osseous metastases of hormone-refractory prostate cancer with external beam radiotherapy and Strontium-89.
De Ruysscher D; Spaas P; Specenier P
Acta Urol Belg; 1996 Sep; 64(3):13-9. PubMed ID: 8946776
[TBL] [Abstract][Full Text] [Related]
6. [Palliative radiotherapy for metastatic bone tumor].
Yoshida K; Hiratsuka J
Clin Calcium; 2006 Apr; 16(4):641- 45. PubMed ID: 16582516
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomized trial: a comparison of the analgesic effect and toxicity of 153Sm radioisotope treatment in monotherapy and combined therapy including local external beam radiotherapy (EBRT) among metastatic castrate resistance prostate cancer (mCRPC) patients with painful bone metastases.
Baczyk M; Milecki P; Pisarek M; Gut P; Antczak A; Hrab M
Neoplasma; 2013; 60(3):328-33. PubMed ID: 23374004
[TBL] [Abstract][Full Text] [Related]
8. Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study.
Makita K; Hamamoto Y; Kanzaki H; Kataoka M; Yamamoto S; Nagasaki K; Ishikawa H; Takata N; Tsuruoka S; Uwatsu K; Kido T
Radiat Oncol; 2021 Nov; 16(1):225. PubMed ID: 34801042
[TBL] [Abstract][Full Text] [Related]
9. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
Nair N
J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
[TBL] [Abstract][Full Text] [Related]
10. External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life.
Di Lorenzo G; Autorino R; Ciardiello F; Raben D; Bianco C; Troiani T; Pizza C; De Laurentiis M; Pensabene M; D'Armiento M; Bianco AR; De Placido S
Oncol Rep; 2003; 10(2):399-404. PubMed ID: 12579279
[TBL] [Abstract][Full Text] [Related]
11. EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy.
Kurosaka S; Satoh T; Chow E; Asano Y; Tabata K; Kimura M; Tsumura H; Matsumoto K; Ishiyama H; Inoue Y; Hayakawa K; Baba S
Ann Nucl Med; 2012 Jul; 26(6):485-91. PubMed ID: 22477263
[TBL] [Abstract][Full Text] [Related]
12. The correlation between palliation of bone pain by intravenous strontium-89 and external beam radiation to linked field in patients with osteoblastic bone metastases.
Ron IG; Stav O; Vishne T; Evan-Sapir E; Soyfer V; Agai R; Cherny N; Kovner F
Am J Clin Oncol; 2004 Oct; 27(5):500-4. PubMed ID: 15596920
[TBL] [Abstract][Full Text] [Related]
13. Systemic radionuclide therapy of bone metastases with strontium-89.
Porter AT; Davis LP
Oncology (Williston Park); 1994 Feb; 8(2):93-6; discussion 96, 99-101. PubMed ID: 8167090
[TBL] [Abstract][Full Text] [Related]
14. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study.
Smeland S; Erikstein B; Aas M; Skovlund E; Hess SL; Fosså SD
Int J Radiat Oncol Biol Phys; 2003 Aug; 56(5):1397-404. PubMed ID: 12873686
[TBL] [Abstract][Full Text] [Related]
15. Hypocalcemia associated with strontium-89 administration in a patient with diffuse bone metastases from neuroendocrine carcinoma.
Mori M; Fadul NA; Bruera E; Dalal S
J Pain Symptom Manage; 2009 May; 37(5):923-9. PubMed ID: 19041217
[TBL] [Abstract][Full Text] [Related]
16. [Strontium chloride (89Sr-chloride) fractional injection method for bone metastases treatment].
Fomin DK; Smirnov IuN; Tararukhina OB; Nazarov AA
Vopr Onkol; 2012; 58(1):116-8. PubMed ID: 22629840
[TBL] [Abstract][Full Text] [Related]
17. Tumoricidal effect and pain relief after concurrent therapy by strontium-89 chloride and zoledronic acid for bone metastases.
Baba K; Kaida H; Hattori C; Muraki K; Kugiyama T; Fujita H; Ishibashi M
Hell J Nucl Med; 2018; 21(1):15-23. PubMed ID: 29550842
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic efficacy of strontium-89-chloride for bone metastatic tumors without bone pain].
Ouyang W; Liu JH; Liu WY
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):390-1. PubMed ID: 17426002
[TBL] [Abstract][Full Text] [Related]
19. Strontium chloride Sr 89 for treating pain from metastatic bone disease.
Nightengale B; Brune M; Blizzard SP; Ashley-Johnson M; Slan S
Am J Health Syst Pharm; 1995 Oct; 52(20):2189-95. PubMed ID: 8564588
[TBL] [Abstract][Full Text] [Related]
20. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.
Porter AT; McEwan AJ; Powe JE; Reid R; McGowan DG; Lukka H; Sathyanarayana JR; Yakemchuk VN; Thomas GM; Erlich LE
Int J Radiat Oncol Biol Phys; 1993 Apr; 25(5):805-13. PubMed ID: 8478230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
